{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T18:40:59Z","timestamp":1783708859548,"version":"3.55.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81960425"],"award-info":[{"award-number":["81960425"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-75612-w","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T08:29:40Z","timestamp":1730190580000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Association of prophylactic low-dose aspirin use with all-cause and cause-specific mortality in cancer patients"],"prefix":"10.1038","volume":"14","author":[{"given":"Hui","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-yi","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-fei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-ping","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,29]]},"reference":[{"issue":"7","key":"75612_CR1","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1097\/cm9.0000000000001474","volume":"134","author":"W Cao","year":"2021","unstructured":"Cao, W., Chen, H. D., Yu, Y. W., Li, N. & Chen, W. Q. Changing profiles of cancer burden worldwide and in China: A secondary analysis of the global cancer statistics 2020. Chin. Med. J. (Engl.) 134 (7), 783\u2013791. https:\/\/doi.org\/10.1097\/cm9.0000000000001474 (2021).","journal-title":"Chin. Med. J. (Engl)"},{"issue":"12","key":"75612_CR2","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1001\/jamaoncol.2019.2996","volume":"5","author":"C Fitzmaurice","year":"2019","unstructured":"Fitzmaurice, C. et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: A systematic analysis for the global burden of disease study. JAMA Oncol. 5 (12), 1749\u20131768. https:\/\/doi.org\/10.1001\/jamaoncol.2019.2996 (2019).","journal-title":"JAMA Oncol."},{"issue":"1","key":"75612_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74 (1), 12\u201349. https:\/\/doi.org\/10.3322\/caac.21820 (2024).","journal-title":"CA Cancer J. Clin."},{"issue":"7","key":"75612_CR4","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00018-022-04430-y","volume":"79","author":"DCN Hall","year":"2022","unstructured":"Hall, D. C. N. & Benndorf, R. A. Aspirin sensitivity of PIK3CA-mutated colorectal cancer: Potential mechanisms revisited. Cell. Mol. Life Sci. 79 (7), 393. https:\/\/doi.org\/10.1007\/s00018-022-04430-y (2022).","journal-title":"Cell. Mol. Life Sci."},{"issue":"2","key":"75612_CR5","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s10555-017-9675-z","volume":"36","author":"A Ornelas","year":"2017","unstructured":"Ornelas, A. et al. Beyond COX-1: The effects of aspirin on platelet biology and potential mechanisms of chemoprevention. Cancer Metastasis Rev. 36 (2), 289\u2013303. https:\/\/doi.org\/10.1007\/s10555-017-9675-z (2017).","journal-title":"Cancer Metastasis Rev."},{"key":"75612_CR6","doi-asserted-by":"publisher","first-page":"1099810","DOI":"10.3389\/fphar.2023.1099810","volume":"14","author":"Y Chen","year":"2023","unstructured":"Chen, Y. et al. Low- or high-dose preventive aspirin use and risk of death from all-cause, cardiovascular disease, and cancer: A nationally representative cohort study. Front. Pharmacol. 14, 1099810. https:\/\/doi.org\/10.3389\/fphar.2023.1099810 (2023).","journal-title":"Front. Pharmacol."},{"key":"75612_CR7","doi-asserted-by":"publisher","first-page":"172762","DOI":"10.1016\/j.ejphar.2019.172762","volume":"866","author":"J Hybiak","year":"2020","unstructured":"Hybiak, J. et al. Aspirin and its pleiotropic application. Eur. J. Pharmacol. 866, 172762. https:\/\/doi.org\/10.1016\/j.ejphar.2019.172762 (2020).","journal-title":"Eur. J. Pharmacol."},{"issue":"9","key":"75612_CR8","doi-asserted-by":"publisher","first-page":"220124","DOI":"10.1098\/rsob.220124","volume":"12","author":"P Elwood","year":"2022","unstructured":"Elwood, P. et al. Aspirin and cancer: Biological mechanisms and clinical outcomes. Open. Biol. 12 (9), 220124. https:\/\/doi.org\/10.1098\/rsob.220124 (2022).","journal-title":"Open. Biol."},{"issue":"1","key":"75612_CR9","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/cam4.4859","volume":"12","author":"M Shahrivar","year":"2023","unstructured":"Shahrivar, M. et al. Low-dose aspirin use and colorectal cancer survival in 32,195 patients-A national cohort study. Cancer Med. 12 (1), 315\u2013324. https:\/\/doi.org\/10.1002\/cam4.4859 (2023).","journal-title":"Cancer Med."},{"issue":"1","key":"75612_CR10","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1093\/ije\/dyz253","volume":"49","author":"CD Sperling","year":"2020","unstructured":"Sperling, C. D. et al. Low-dose aspirin use and endometrial cancer mortality-a Danish nationwide cohort study. Int. J. Epidemiol. 49 (1), 330\u2013337. https:\/\/doi.org\/10.1093\/ije\/dyz253 (2020).","journal-title":"Int. J. Epidemiol."},{"issue":"48","key":"75612_CR11","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1093\/eurheartj\/ehz766","volume":"40","author":"KM Sturgeon","year":"2019","unstructured":"Sturgeon, K. M. et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur. Heart J. 40 (48), 3889\u20133897. https:\/\/doi.org\/10.1093\/eurheartj\/ehz766 (2019).","journal-title":"Eur. Heart J."},{"issue":"49","key":"75612_CR12","doi-asserted-by":"publisher","first-page":"21829","DOI":"10.1002\/anie.202004317","volume":"59","author":"B Yang","year":"2020","unstructured":"Yang, B. & Shi, J. Developing new cancer nanomedicines by repurposing old drugs. Angew Chem. Int. Ed. Engl. 59 (49), 21829\u201321838. https:\/\/doi.org\/10.1002\/anie.202004317 (2020).","journal-title":"Angew Chem. Int. Ed. Engl."},{"issue":"11","key":"75612_CR13","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41569-019-0225-y","volume":"16","author":"C Patrono","year":"2019","unstructured":"Patrono, C. & Baigent, C. Role of aspirin in primary prevention of cardiovascular disease. Nat. Rev. Cardiol. 16 (11), 675\u2013686. https:\/\/doi.org\/10.1038\/s41569-019-0225-y (2019).","journal-title":"Nat. Rev. Cardiol."},{"issue":"5","key":"75612_CR14","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.eururo.2017.01.044","volume":"72","author":"MK Downer","year":"2017","unstructured":"Downer, M. K. et al. Regular aspirin use and the risk of lethal prostate cancer in the physicians\u2019 health study. Eur. Urol. 72 (5), 821\u2013827. https:\/\/doi.org\/10.1016\/j.eururo.2017.01.044 (2017).","journal-title":"Eur. Urol."},{"issue":"12","key":"75612_CR15","doi-asserted-by":"publisher","first-page":"814","DOI":"10.7326\/m15-2117","volume":"164","author":"J Chubak","year":"2016","unstructured":"Chubak, J. et al. Aspirin for the prevention of cancer incidence and mortality: Systematic evidence reviews for the U.S. preventive services task force. Ann. Intern. Med. 164 (12), 814\u2013825. https:\/\/doi.org\/10.7326\/m15-2117 (2016).","journal-title":"Ann. Intern. Med."},{"key":"75612_CR16","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.3332\/ecancer.2021.1258","volume":"15","author":"PC Elwood","year":"2021","unstructured":"Elwood, P. C. et al. Aspirin and cancer survival: A systematic review and meta-analyses of 118 observational studies of aspirin and 18 cancers. Ecancermedicalscience 15, 1258. https:\/\/doi.org\/10.3332\/ecancer.2021.1258 (2021).","journal-title":"Ecancermedicalscience"},{"issue":"33","key":"75612_CR17","doi-asserted-by":"publisher","first-page":"e26870","DOI":"10.1097\/md.0000000000026870","volume":"100","author":"J Liu","year":"2021","unstructured":"Liu, J., Zheng, F., Yang, M., Wu, X. & Liu, A. Effect of aspirin use on survival benefits of breast cancer patients: A meta-analysis. Med. (Baltim) 100 (33), e26870. https:\/\/doi.org\/10.1097\/md.0000000000026870 (2021).","journal-title":"Med. (Baltim)."},{"issue":"16","key":"75612_CR18","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","volume":"379","author":"L Bowman","year":"2018","unstructured":"Bowman, L. et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl. J. Med. 379 (16), 1529\u20131539. https:\/\/doi.org\/10.1056\/NEJMoa1804988 (2018).","journal-title":"N Engl. J. Med."},{"issue":"16","key":"75612_CR19","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1001\/jama.2022.3337","volume":"327","author":"JM Guirguis-Blake","year":"2022","unstructured":"Guirguis-Blake, J. M., Evans, C. V., Perdue, L. A., Bean, S. I. & Senger, C. A. Aspirin use to prevent cardiovascular disease and colorectal cancer: Updated evidence report and systematic review for the US preventive services task force. Jama 327 (16), 1585\u20131597. https:\/\/doi.org\/10.1001\/jama.2022.3337 (2022).","journal-title":"Jama"},{"issue":"16","key":"75612_CR20","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa1803955","volume":"379","author":"JJ McNeil","year":"2018","unstructured":"McNeil, J. J. et al. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl. J. Med. 379 (16), 1519\u20131528. https:\/\/doi.org\/10.1056\/NEJMoa1803955 (2018).","journal-title":"N Engl. J. Med."},{"issue":"2","key":"75612_CR21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s40256-014-0100-5","volume":"15","author":"C Brotons","year":"2015","unstructured":"Brotons, C., Benamouzig, R., Filipiak, K. J., Limmroth, V. & Borghi, C. A systematic review of aspirin in primary prevention: Is it time for a new approach? Am. J. Cardiovasc. Drugs 15 (2), 113\u2013133. https:\/\/doi.org\/10.1007\/s40256-014-0100-5 (2015).","journal-title":"J. Cardiovasc. Drugs"},{"issue":"2","key":"75612_CR22","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/med.20182","volume":"31","author":"MN Khan","year":"2011","unstructured":"Khan, M. N. & Lee, Y. S. Cyclooxygenase inhibitors: Scope of their use and development in cancer chemotherapy. Med. Res. Rev. 31 (2), 161\u2013201. https:\/\/doi.org\/10.1002\/med.20182 (2011).","journal-title":"Med. Res. Rev."},{"issue":"2","key":"75612_CR23","doi-asserted-by":"publisher","first-page":"953","DOI":"10.3892\/or.2017.5353","volume":"37","author":"Y He","year":"2017","unstructured":"He, Y. et al. Combined effects of atorvastatin and aspirin on growth and apoptosis in human prostate cancer cells. Oncol. Rep. 37 (2), 953\u2013960. https:\/\/doi.org\/10.3892\/or.2017.5353 (2017).","journal-title":"Oncol. Rep."},{"issue":"12","key":"75612_CR24","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1158\/1535-7163.Mct-16-0074","volume":"15","author":"Y Huang","year":"2016","unstructured":"Huang, Y. et al. Antitumor and antiangiogenic effects of aspirin-PC in ovarian cancer. Mol. Cancer Ther. 15 (12), 2894\u20132904. https:\/\/doi.org\/10.1158\/1535-7163.Mct-16-0074 (2016).","journal-title":"Mol. Cancer Ther."},{"issue":"20","key":"75612_CR25","doi-asserted-by":"publisher","first-page":"6267","DOI":"10.1158\/1078-0432.Ccr-17-0242","volume":"23","author":"X Dai","year":"2017","unstructured":"Dai, X. et al. Aspirin inhibits cancer metastasis and angiogenesis via targeting heparanase. Clin. Cancer Res. 23 (20), 6267\u20136278. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-0242 (2017).","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"75612_CR26","doi-asserted-by":"publisher","first-page":"e0152402","DOI":"10.1371\/journal.pone.0152402","volume":"11","author":"PC Elwood","year":"2016","unstructured":"Elwood, P. C. et al. Aspirin in the treatment of cancer: Reductions in metastatic spread and in mortality: A systematic review and meta-analyses of published studies. PLoS One 11 (4), e0152402. https:\/\/doi.org\/10.1371\/journal.pone.0152402 (2016).","journal-title":"PLoS One"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75612-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75612-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75612-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T08:33:50Z","timestamp":1730190830000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75612-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["75612"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-75612-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,29]]},"assertion":[{"value":"26 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The research protocol was espoused by the Institutional Review Board of the National Center for Health Statistics (NCHS), and informed consent was signed by all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and Consent Statements"}},{"value":"All authors agree to publish this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"25918"}}